COMMUNIQUÉS West-GlobeNewswire

IBA Notice of Full Year 2025 Results and Conference Call
13/03/2026
FY25 results webcast to take place on Friday, 27 March 2026 at 3pm CET Louvain-la-Neuve, Belgium, 13 March 2026 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, [...]
IBA : Publication des résultats annuels 2025 et conférence web
13/03/2026
La conférence sur les résultats de l’exercice 2025 aura lieu le vendredi 27 mars 2026 à 15h00, heure de Bruxelles Louvain-la-Neuve, Belgique, le 13 mars 2026 - IBA (Ion Beam Applications S.A le leader mondial des [...]
Novonesis issues EUR 1.7 billion senior unsecured notes
13/03/2026
On March 12, 2026, Novonesis, through Novozymes A/S, successfully priced and closed an aggregate principal amount of EUR 1.7 billion senior unsecured notes (the "Notes"). The issuance was completed under the newly [...]
Eupraxia Pharmaceuticals Reports Fourth Quarter 2025 Financial Results
13/03/2026
VICTORIA, British Columbia, March 12, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary [...]
Indivior Prices Upsized $450.0 Million Convertible Senior Notes Offering
13/03/2026
RICHMOND, Va., March 12, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced the pricing of its offering of $450,000,000 aggregate principal amount of 0.625% convertible senior notes [...]
Xenon Pharmaceuticals Announces Closing of $747.5 Million Upsized Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
12/03/2026
VANCOUVER, British Columbia and BOSTON, MA, March 12, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical [...]
VitalHub Announces Updated Date for Fourth Quarter and Annual 2025 Results
12/03/2026
TORONTO, March 12, 2026 (GLOBE NEWSWIRE) -- Vitalhub Corp. (TSX:VHI) (OTCQX:VHIBF) (the “Company” or “VitalHub”) announced today that it has updated the date for the release of its financial results for the fourth [...]
IN8bio Reports Fourth Quarter and Full-Year 2025 Financial Results - Highlights Durable Survival Improvements in Glioblastoma, Advancing Pipeline and Strengthened Financial Position for 2026
12/03/2026
Presented updated glioblastoma (“GBM”) data demonstrating durable survival and a favorable safety profile across Phase 1 and Phase 2 programs, with repeat dosing of DeltEx™ Drug-Resistant Immunotherapy γδ T cells (“DRI [...]
Surgery Partners, Inc. Names Lloyd Dean to Board of Directors
12/03/2026
BRENTWOOD, Tenn., March 12, 2026 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) (“Surgery Partners” or the “Company”) recently announced that Lloyd Dean has been appointed to serve as an independent director [...]
BeautyHealth Reports Full Year and Fourth Quarter 2025 Financial Results
12/03/2026
LONG BEACH, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- The Beauty Health Company (NASDAQ: SKIN) (“BeautyHealth” or the "Company"), home to flagship brand Hydrafacial, today announced financial results for the full year [...]
Vaxart Provides Business Update and Reports Full Year 2025 Financial Results
12/03/2026
Topline data from 400-person sentinel cohort of the Phase 2b COVID-19 trial anticipated early Q2 2026 Published positive clinical results in the first quarter of 2026 demonstrating oral norovirus vaccine candidate was [...]
Dianthus Therapeutics, Inc. Announces Closing of its Upsized $719 Million Underwritten Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
12/03/2026
NEW YORK and WALTHAM, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH) (“Dianthus” or the “Company”), a clinical-stage biotechnology company dedicated to developing next-generation [...]
The Joint Corp. Reports 2025 Fourth Quarter and Full Year Financial Results
12/03/2026
- Fourth Quarter Revenues Increase 3.1% Year over Year - - Full Year Revenues of $54.9 Million, Net Income of $2.9 Million and a 13.9% Increase in Adjusted EBITDA to $13.0 Million - SCOTTSDALE, Ariz., March 12, 2026 ( [...]
Capricor Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
12/03/2026
Deramiocel BLA for Duchenne muscular dystrophy under U.S. FDA review with PDUFA target action date of August 22, 2026 Pivotal HOPE-3 Phase 3 trial achieved primary endpoint (PUL v2.0) and key secondary cardiac endpoint [...]
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
12/03/2026
Announced data from cohort 4 of soquelitinib atopic dermatitis Phase 1 trial demonstrating positive safety and efficacy results, including in patients who have received prior systemic therapy Initiated soquelitinib [...]
Korro Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
12/03/2026
Nominated KRRO-121 development candidate for the potential treatment of hyperammonemia in patients with urea cycle disorders and hepatic encephalopathy Advanced GalNAc-conjugated oligonucleotide for alpha-1 antitrypsin [...]
Health Catalyst Reports Fourth Quarter and Year End 2025 Results
12/03/2026
SALT LAKE CITY, March 12, 2026 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. (“Health Catalyst,” Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today reported [...]
Erasca Reports Fourth Quarter and Full Year 2025 Business Updates and Financial Results
12/03/2026
Encouraging early clinical activity observed during ERAS-0015 dose escalation, including ongoing responses across multiple RAS-mutant tumors with favorable safety, tolerability, and pharmacokinetics Phase 1 monotherapy [...]
Allogene Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update
12/03/2026
Pivotal, Randomized Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First Line (1L) Consolidation in Large B-Cell Lymphoma (LBCL) Positions Company at the Forefront of MRD-Guided 1L Consolidation [...]

Pages